Stocktoria
biote Corp. BTMD
biote Corp. (BTMD) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 2.57% (safety: safe). FY2025 revenue was $192.2M at a 14.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.09 |
| Retained earnings / assets | -0.46 |
| EBIT / assets | 0.33 |
| Equity / liabilities | -0.37 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BTMD | biote Corp. | 5/9 | 0.92 | 2.5 | -2.5% |
| CRON | Cronos Group Inc. | 6/9 | — | — | +19.5% |
| GLAS | Glass House Brands Inc. | 3/9 | -1.45 | — | -9.4% |
| MRMD | MARIMED INC. | 4/9 | -1.76 | — | +1.3% |
| NAII | NATURAL ALTERNATIVES INTERNATIONAL INC | 5/9 | 3.07 | — | +14.1% |
| NAGE | Niagen Bioscience, Inc. | 5/9 | 3.42 | 15.7 | +29.9% |
| JUSHF | Jushi Holdings Inc. | 3/9 | -4.96 | — | +2.1% |
About biote Corp.
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.
FAQ
Is BTMD financially healthy?
biote Corp.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does BTMD pay a dividend, and is it safe?
Yes. biote Corp. pays a dividend yielding about 2.57% with a 6.4% payout ratio, rated “safe” for safety.
How profitable is BTMD?
In FY2025, biote Corp. had a net margin of 14.1%.
What is BTMD's P/E ratio?
biote Corp.'s trailing price-to-earnings (P/E) ratio is about 2.5×, based on its latest annual earnings.
What is the analyst price target for BTMD?
The average Wall-Street price target for biote Corp. is $2.99, about 110.3% above the recent price, from 5 analysts.
Is BTMD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on biote Corp.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone, a P/E of about 2.5×, a dividend yield of 2.57%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.